vs

Side-by-side financial comparison of AIR LEASE CORP (AL) and CareDx, Inc. (CDNA). Click either name above to swap in a different company.

AIR LEASE CORP is the larger business by last-quarter revenue ($140.8M vs $117.7M, roughly 1.2× CareDx, Inc.). AIR LEASE CORP runs the higher net margin — 128.5% vs 2.4%, a 126.1% gap on every dollar of revenue. On growth, AIR LEASE CORP posted the faster year-over-year revenue change (90.4% vs 39.0%). AIR LEASE CORP produced more free cash flow last quarter ($342.1M vs $514.0K). Over the past eight quarters, AIR LEASE CORP's revenue compounded faster (69.6% CAGR vs 12.9%).

Air Lease Corporation (ALC) is an American aircraft leasing company founded in 2010 and headed by Steven F. Udvar-Házy. Air Lease purchases new commercial aircraft through direct orders from Boeing, Airbus, Embraer and ATR, and leases them to its airline customers worldwide through specialized aircraft leasing and financing.

CareDx, Inc. is a leading precision medicine company dedicated to organ transplant patient care. It develops and commercializes diagnostic tests for rejection surveillance, digital health management tools, and supportive clinical services, catering to transplant clinicians, patients, and healthcare systems across North America and European core markets.

AL vs CDNA — Head-to-Head

Bigger by revenue
AL
AL
1.2× larger
AL
$140.8M
$117.7M
CDNA
Growing faster (revenue YoY)
AL
AL
+51.5% gap
AL
90.4%
39.0%
CDNA
Higher net margin
AL
AL
126.1% more per $
AL
128.5%
2.4%
CDNA
More free cash flow
AL
AL
$341.6M more FCF
AL
$342.1M
$514.0K
CDNA
Faster 2-yr revenue CAGR
AL
AL
Annualised
AL
69.6%
12.9%
CDNA

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
AL
AL
CDNA
CDNA
Revenue
$140.8M
$117.7M
Net Profit
$180.9M
$2.8M
Gross Margin
Operating Margin
1.0%
Net Margin
128.5%
2.4%
Revenue YoY
90.4%
39.0%
Net Profit YoY
60.2%
EPS (diluted)
$1.49
$0.05

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AL
AL
CDNA
CDNA
Q1 26
$117.7M
Q4 25
$140.8M
$108.4M
Q3 25
$44.5M
$100.1M
Q2 25
$53.0M
$86.7M
Q1 25
$92.9M
$84.7M
Q4 24
$74.0M
$86.6M
Q3 24
$65.0M
$82.9M
Q2 24
$57.8M
$92.3M
Net Profit
AL
AL
CDNA
CDNA
Q1 26
$2.8M
Q4 25
$180.9M
$-4.1M
Q3 25
$146.5M
$1.7M
Q2 25
$385.2M
$-8.6M
Q1 25
$375.8M
$-10.4M
Q4 24
$112.9M
$87.7M
Q3 24
$104.0M
$-10.6M
Q2 24
$102.9M
$-4.6M
Operating Margin
AL
AL
CDNA
CDNA
Q1 26
1.0%
Q4 25
-5.6%
Q3 25
-0.2%
Q2 25
-12.8%
Q1 25
-15.8%
Q4 24
97.5%
Q3 24
-16.6%
Q2 24
-7.9%
Net Margin
AL
AL
CDNA
CDNA
Q1 26
2.4%
Q4 25
128.5%
-3.8%
Q3 25
329.2%
1.7%
Q2 25
726.9%
-9.9%
Q1 25
404.5%
-12.2%
Q4 24
152.7%
101.3%
Q3 24
160.0%
-12.8%
Q2 24
178.2%
-5.0%
EPS (diluted)
AL
AL
CDNA
CDNA
Q1 26
$0.05
Q4 25
$1.49
$-0.08
Q3 25
$1.21
$0.03
Q2 25
$3.33
$-0.16
Q1 25
$3.26
$-0.19
Q4 24
$0.83
$1.60
Q3 24
$0.82
$-0.20
Q2 24
$0.81
$-0.09

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AL
AL
CDNA
CDNA
Cash + ST InvestmentsLiquidity on hand
$466.4M
$77.9M
Total DebtLower is stronger
$19.7B
Stockholders' EquityBook value
$8.5B
Total Assets
$32.9B
$411.1M
Debt / EquityLower = less leverage
2.33×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AL
AL
CDNA
CDNA
Q1 26
$77.9M
Q4 25
$466.4M
$177.2M
Q3 25
$452.2M
$194.2M
Q2 25
$454.8M
$186.3M
Q1 25
$456.6M
$230.9M
Q4 24
$472.6M
$260.7M
Q3 24
$460.8M
$240.9M
Q2 24
$454.1M
$228.9M
Total Debt
AL
AL
CDNA
CDNA
Q1 26
Q4 25
$19.7B
Q3 25
$20.2B
Q2 25
$20.3B
Q1 25
$19.9B
Q4 24
$20.2B
Q3 24
$20.2B
$0
Q2 24
$19.7B
$0
Stockholders' Equity
AL
AL
CDNA
CDNA
Q1 26
Q4 25
$8.5B
$303.1M
Q3 25
$8.3B
$311.1M
Q2 25
$8.2B
$327.4M
Q1 25
$7.9B
$379.3M
Q4 24
$7.5B
$378.4M
Q3 24
$7.7B
$273.2M
Q2 24
$7.3B
$264.7M
Total Assets
AL
AL
CDNA
CDNA
Q1 26
$411.1M
Q4 25
$32.9B
$413.2M
Q3 25
$33.4B
$432.3M
Q2 25
$33.3B
$444.3M
Q1 25
$32.4B
$489.6M
Q4 24
$32.3B
$491.1M
Q3 24
$32.2B
$477.0M
Q2 24
$31.0B
$466.8M
Debt / Equity
AL
AL
CDNA
CDNA
Q1 26
Q4 25
2.33×
Q3 25
2.42×
Q2 25
2.47×
Q1 25
2.53×
Q4 24
2.68×
Q3 24
2.63×
0.00×
Q2 24
2.69×
0.00×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AL
AL
CDNA
CDNA
Operating Cash FlowLast quarter
$414.1M
$4.3M
Free Cash FlowOCF − Capex
$342.1M
$514.0K
FCF MarginFCF / Revenue
242.9%
0.4%
Capex IntensityCapex / Revenue
51.1%
Cash ConversionOCF / Net Profit
2.29×
1.54×
TTM Free Cash FlowTrailing 4 quarters
$1.5B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AL
AL
CDNA
CDNA
Q1 26
$4.3M
Q4 25
$414.1M
$21.4M
Q3 25
$458.6M
$37.4M
Q2 25
$473.6M
$9.9M
Q1 25
$388.3M
$-26.6M
Q4 24
$430.0M
$21.9M
Q3 24
$461.9M
$12.5M
Q2 24
$413.8M
$18.9M
Free Cash Flow
AL
AL
CDNA
CDNA
Q1 26
$514.0K
Q4 25
$342.1M
Q3 25
$412.3M
Q2 25
$427.1M
Q1 25
$315.5M
Q4 24
$326.8M
Q3 24
$369.8M
Q2 24
$346.4M
FCF Margin
AL
AL
CDNA
CDNA
Q1 26
0.4%
Q4 25
242.9%
Q3 25
926.6%
Q2 25
806.0%
Q1 25
339.5%
Q4 24
441.8%
Q3 24
569.1%
Q2 24
599.5%
Capex Intensity
AL
AL
CDNA
CDNA
Q1 26
Q4 25
51.1%
Q3 25
104.1%
Q2 25
87.8%
Q1 25
78.4%
Q4 24
139.6%
Q3 24
141.7%
Q2 24
116.7%
Cash Conversion
AL
AL
CDNA
CDNA
Q1 26
1.54×
Q4 25
2.29×
Q3 25
3.13×
22.30×
Q2 25
1.23×
Q1 25
1.03×
Q4 24
3.81×
0.25×
Q3 24
4.44×
Q2 24
4.02×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AL
AL

Segment breakdown not available.

CDNA
CDNA

Financial Results Total$85.0M72%
Patient and digital solutions revenue$16.0M14%
Product revenue$10.3M9%
Other$6.4M5%

Related Comparisons